OncorusÂ Inc (ONCR) Peer Comparison

$0.13

$0.00 (-3.08%)

As on 29-Dec-2023 14:55EDT

Market cap

$3 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

0.1

Div. Yield

0 %

Edit

	OncorusÂ Inc (ONCR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Market cap ($ Mln)	3	17,326	13,400	12,305	12,277
Revenue ($ Mln)	--	2,782	2,436	670	1,664
Net Profit ($ Mln)	-94.27	491.50	860.62	-319.95	413.60
Net Margin (%)	--	17.67	35.33	-47.79	24.86
RoE (%)	-169.67	110.09	42.98	-71.14	430.03
Price to Earnings	--	36.49	17.01	--	31.17
Price-To-Book	0.11	39.43	7.27	26.44	83.92

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	OncorusÂ Inc (ONCR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Operating Revenue	0.00	1,460.00	1,611.06	243.23	660.12
Cost of Revenue	0.00	1,027.56	57.91	10.42	139.30
Gross Profit	--	432.44	1,553.15	243.23	520.81
Operating Expenses	73.85	153.74	1,351.67	421.74	253.28
Operating Profit (EBIT)	-59.27	278.70	201.48	-178.51	267.53
Other Income	0.00	7.07	-0.20	0.77	-1.67
Profit before Tax	-90.54	282.86	234.35	-172.71	248.92
Provision for Tax	3.73	37.49	52.07	3.79	46.79
Profit after Tax (Net Income)	-94.27	245.37	182.28	-176.49	202.13
Minority Interest	0.00	--	--	19.82	--
Consolidated Profit	-59.64	245.37	182.28	-176.06	202.13

Liabilities ($ Mln)

	OncorusÂ Inc (ONCR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Shareholder's Funds	31.12	386.39	2,488.43	398.52	169.80
Minority Interest	0.00	--	--	19.82	--
Non-Current Liabilities	47.52	162.64	258.70	134.75	1,540.92
Current Liabilities	31.11	803.47	324.36	138.85	130.79
Total Liabilities	145.59	1,352.50	3,071.49	691.94	1,841.51

Assets ($ Mln)

	OncorusÂ Inc (ONCR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Non-Current Assets	63.08	1,018.53	1,452.73	286.64	1,102.50
Current Assets	46.67	333.96	1,618.76	405.30	739.01
Total Assets	145.59	1,352.50	3,071.49	691.94	1,841.51
Total Debt*	69.25	188.87	190.17	81.58	1,506.10
Net Current Assets	15.56	-469.51	1,294.40	302.30	608.22

Cashflow ($ Mln)

	OncorusÂ Inc (ONCR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Cash From Operating Activities	-61.69	388.05	362.61	-136.13	240.11
Cash Flow from Investing Activities	--	-38.74	-524.41	-5.42	-487.01
Cash from Financing Activities	19.65	-775.78	0.59	65.19	362.37
Net Cash Inflow / Outflow	--	-426.47	-161.21	-76.36	115.48

Ratios

Profitability Ratios

	OncorusÂ Inc (ONCR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
ROCE (%)	-50.35	29.58	7.38	-38.60	14.70
ROE (%)	-169.67	36.64	7.76	-43.72	110.23
ROA (%)	-57.20	16.29	6.41	-25.18	13.72
EBIT Margin (%)	--	--	--	--	--
Net Margin (%)	--	16.73	11.32	-72.33	30.70
Cash Profit Margin (%)	--	--	--	--	--

Growth Ratios

	OncorusÂ Inc (ONCR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Revenue Growth (%)	--	0.28	0.12	0.76	0.49
EBIT Growth (%)	15.29	--	--	--	--
Net Profit Growth (%)	-34.97	34.93	-21.11	-25.31	-49.81
EPS Growth (%)	-33.46	0.57	-0.21	-0.24	-0.48
Book Value Growth (%)	-72.76	--	--	--	--

Valuation Ratios

	OncorusÂ Inc (ONCR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Price / Earnings	-0.08	28.07	28.45	-19.80	39.02
Price / Book Value	0.11	17.82	2.08	8.77	46.45
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-0.17	22.87	18.29	-19.04	28.62
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	OncorusÂ Inc (ONCR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debt to Equity	0.00	0.49	0.08	0.20	8.87
Short term debt to equity ratio	0.70	0.13	0.01	0.01	0.08
Current Ratio	1.50	0.42	4.99	2.92	5.65
Quick Ratio	1.50	--	4.89	3.07	4.88
Interest Coverage	-32.70	98.37	3.75	-35.47	15.69

Operating Efficiency Ratios

	OncorusÂ Inc (ONCR)	Medpace Holdings (MEDP)	Exelixis (EXEL)	Arrowhead Pharmaceuticals (ARWR)	Halozyme Therapeutics (HALO)
Debtors to sales (%)	--	17.36	13.33	0.58	35.00
Asset Turnover	0.00	0.97	0.57	0.35	0.45
Receivable days	--	55.02	56.39	8.76	89.10
Inventory Days	--	--	191.72	-302.34	201.93
Payable days	--	10.44	179.52	215.99	25.22
Cash Conversion Cycle	--	--	68.58	-509.57	265.81

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly